

Technology Appraisal Committee B Interests Register

Topic: Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

Publication Date: Tbc.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley-Price	TAC B Member	Direct Financial	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505). It has also been appraised to enable exit the CDF (ID1635).	10/12/2023	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
Rakesh Popat	Clinical Expert	Direct – financial Indirect - Financial	Consultancy: GSK, Janssen, Sanofi, Galapagos, Roche Honoraria: Abbvie, Janssen, GSK, Pfizer, BMS. Research Support (to institution): GSK, Pfizer. Travel Support: Janssen, GSK Leeds University has received grant funding for the ProMMise trial that I lead	08/01/2024	It was agreed that Rakesh Popat's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).		providing expert advice to the committee.
David Robinson	Patient Expert	Indirect – Financial	We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).	08/01/2024	It was agreed that David Robinson's declaration would not prevent him from providing expert advice to the committee.